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Abstract. The objective was to analyze the factors that influence self-perceived quality of life (QoL) in patients with
Alzheimer’s disease (AD), contrasting two different longitudinal models. A total of 127 patients were followed up over
24 months. The instruments applied were: Quality of Life in Alzheimer’s Disease scale (QoL-AD), Geriatric Depression
Scale-15, Anosognosia Questionnaire-Dementia, Disability Assessment in Dementia, Neuropsychiatric Inventory, and the
Mini-Mental State Examination. Two models for grouping patients were tested: 1) Baseline score on the QoL-AD (QoL-
Baseline), and 2) Difference in QoL-AD score between baseline and follow-up (QoL-Change). Generalized estimating
equations were used to analyze longitudinal data, and multinomial regression analyses were performed. Over the follow-up
period the QoL-Baseline model showed greater variability between groups (Wald χ2 = 172.3, p< 0.001) than did the QoL-
Change model (Wald χ2 = 1.7, p= 0.427). In the QoL-Baseline model the predictive factors were greater depression (odds
ratio [OR] = 1.20; 95% CI: 1.00–1.45) and lower functional ability (OR = 0.92; 95% CI: 0.85–0.99) for the Low QoL group
(< 33 QoL-AD), and less depression (OR = 0.68; 95% CI: 0.52–0.88), more anosognosia (OR = 1.07; 95% CI: 1.01–1.13),
and fewer neuropsychiatric symptoms (OR = 0.95; 95% CI: 0.91–0.99) for the High-QoL group (>37 QoL-AD). The model
based on baseline scores (QoL-Baseline) was better than the QoL-Change model in terms of identifying trajectories and
predictors of QoL in AD.
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INTRODUCTION
In its report, Dementia: A Public Health Priority,
the World Health Organization [1] highlights the
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need to develop programs that can improve the social
wellbeing and quality of life (QoL) of people with
dementia. Consequently, it is important to identify
the factors that influence QoL so as to design inter-
ventions that might improve it.
Among research that has examined predictors of
change in the QoL of patients with dementia, longitu-
dinal studies are of particular interest. The majority of
these studies have found, when considering samples
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as a whole, that mean QoL scores remain relatively
stable over time [2–14], although some research con-
ducted in residential settings has reported a decrease
[15–17].
The factors associated with perceived QoL are
consistent across some studies. Greater depression
appears to be the most relevant aspect and it is asso-
ciated with a deteriorating QoL over time [2, 6–8, 18].
A greater number of neuropsychiatric symptoms
(higher scores on the NPI) is also associated with
poorer perceived QoL [5, 11, 17], whereas better
functional ability correlates with higher QoL scores
[3, 6] Cognitive changes appear to have only a weak
or no effect [12, 19].
Many longitudinal studies also distinguish sub-
groups of patients according to whether their
perceived QoL deteriorates, remains stable, or
improves over time. The combined data of five com-
munity studies [3, 7–9, 13], with a total sample of
417 people, indicate that QoL scores deteriorated in
28.2%, remained stable in 35.9%, and improved in
35.7%. Across six studies carried out in residential
care settings [2, 4, 14–17], with a total sample of
906 elders, QoL scores deteriorated in 41%, remained
stable in 27.2%, and improved in 31.7%.
Analyzing the self-perceived QoL of patients is,
however, a complex task [15] due to the considerable
individual variability and small effect sizes involved.
It should also be noted that the severity of dementia
does not seem to affect QoL scores [12, 13]. Base-
line QoL appears to have a predictive value, although
studies report contrasting results as regards the direc-
tion of the effect: While some studies have found that
higher QoL at baseline was associated with better
QoL at follow-up [2, 6, 7, 9, 15, 16], others, mostly
in residential settings, report a reduction in perceived
QoL among those with higher baseline QoL scores
[4, 14, 17].
Despite this evidence, most studies aimed at
analyzing the evolution of QoL have used the
total QoL score or have defined groups based on
how their scores changed (QoL-Change: Deterio-
ration/stability/improvement). However, given the
predictive capacity of baseline QoL and the stabil-
ity of scores over time, it might be more useful to
define groups on the basis of their baseline score
(Low, Medium, and High QoL), to analyze how these
scores change, and to identify predictive factors for
each group at the time of the baseline assessment.
This distribution of groups could then be compared
with that used by the majority of studies (i.e., QoL-
Change: Decreased, No change, Increased).
The hypothesis underlying the present study is that
a model in which groups are defined according to
their baseline QoL score would be better at identi-
fying the trajectories and predictive factors of QoL,
and that these factors (e.g., depression, neuropsychi-
atric symptoms, anosognosia, and functional ability)
would not be the same for each group.
Given the wide range of factors that are potentially
involved and the various models that have been used
to study changes in the perceived QoL of patients
with dementia, the present study had the following
objectives: 1) to analyze the factors that influence
self-perceived QoL when the total sample of patients
is considered; 2) to analyze the factors associated with
self-perceived QoL when three subgroups are estab-
lished on the basis of the baseline QoL score (QoL-
Baseline model) and according to the change in score
over time (QoL-Change model); and 3) to assess
which of these models is best in terms of identifying
the trajectory and predictors of QoL scores over time.
METHODS
Design and study population
This was a longitudinal study involving a 24-month
follow-up of a consecutive sample of outpatients
seen at the Dementia Unit (Department of Neurol-
ogy) of Bellvitge University Hospital (Hospitalet de
Llobregat, Barcelona). They were all diagnosed as
either AD according to the criteria of the Diagnostic
and Statistical Manual of Mental Disorders (DSM-5)
[20] or probable AD according to the criteria of the
National Institute of Neurological and Communica-
tive Disorders and Stroke / Alzheimer’s Disease and
Related Disorders Associations [21]. In addition, they
all scored between 10 and 28 on the Mini-Mental
State Examination (MMSE) [22], thereby enabling a
quality-of-life scale (QoL-AD) [23] to be adminis-
tered. The main caregiver was defined as the person
with ongoing responsibility for helping the patient
with activities of daily living (ADL). All the care-
givers were relatives of the patients.
Patients were excluded if they presented vascular
or traumatic events, alcohol or substance dependence
or abuse, and if they had severe communication prob-
lems that prevented them from responding adequately
to the assessment instruments. Informed consent was
obtained for all participants. The study was approved
by the hospital’s Clinical Research Ethics Committee
(ref. PR162/10).
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Instruments
Socio-demographic data for patients were gath-
ered using a structured questionnaire designed by the
researchers.
• Quality of life. The Quality of Life in
Alzheimer’s Disease (QoL-AD) scale [23] was
used to explore patients’ own views regarding
their quality of life. This instrument comprises
13 items that refer to different aspects of the
patient’s wellbeing. Each item is scored on a
Likert-type scale ranging from 1 (poor) to 4
(excellent), yielding a total score between 13 and
52 (the higher the score the better the perceived
quality of life).
• Behavioral and psychological symptoms of
dementia. This aspect was evaluated by means
of the Neuropsychiatric Inventory (NPI) [24],
which comprises 12 subscales that assess the
frequency and severity of 12 neuropsychiatric
symptoms, based on information provided by
caregivers. Scores range from 0 to 144, and the
higher the score the greater the frequency and
severity of neuropsychiatric symptoms.
• Anosognosia. The Anosognosia Questionnaire-
Dementia (AQ-D) [25] was administered to
patients and caregivers. It comprises 30 items
referring to cognitive/functional deficits and
changes in the patient’s behavior, with each item
being rated according to the frequency of occur-
rence, from 0 (never) to 3 (always). The total
score therefore ranges from 0 to 90. The degree
of anosognosia is estimated on the basis of the
difference between patient and caregiver scores;
the greater the difference the greater the anosog-
nosia.
• Cognitive assessment of the patient. This was
based on the MMSE [22], a brief cognitive
assessment tool whose score ranges from 0 to
30 (the lower the score the greater the cognitive
deterioration). Patients’ scores were corrected
for age and level of education [26].
• Depression in the patient. This was assessed
using the Geriatric Depression Scale (GDS), in
its 15-item format [27]. The cut-off score for
probable depression is 6, while a score of 10 or
higher is indicative of depression. The 15-item
version of the GDS has been previously used to
assess depression in patients with AD [28, 29].
• Functional assessment of the patient. The Dis-
ability Assessment for Dementia (DAD) [30]
is a measure of basic and instrumental ADL
and it was administered to the main caregiver.
The DAD comprises 40 items and its total score
ranges from 40 to 80 (the higher the score the
greater the patient’s functional ability).
• Severity of dementia. This was based on the cri-
teria of the Global Deterioration Scale (GDS)
[31], a tool designed to determine the stage of
a patient’s dementia. Patients were excluded if
they were classified as either GDS 7, due to the
severity of their dementia, or GDS 3, due to the
possible confusion with mild cognitive impair-
ment.
Procedure
Neurologists from the Dementia Unit of Bellvitge
University Hospital selected eligible patients accord-
ing to the inclusion criteria and then determined their
stage of dementia using the GDS. The initial sample
was recruited between January and December 2011,
with a 24-month follow-up assessment being con-
ducted in May 2014. The baseline sample comprised
221 patients, of whom 127 were able to be re-assessed
at 24 months. Regarding the 94 (42.5%) patients
lost to follow-up, 27 (28.7%) had entered residential
care, 31 (32.9%) decided not to participate any fur-
ther, 2 (2.1%) had changed address, and 34 (36.1%)
had died. The present study only uses data from
the 127 participants who completed the 24-month
follow-up.
The aims of the study were explained to all
participants prior to the baseline interview, and
informed consent was obtained from both patients
and caregivers before proceeding. Patients and their
caregivers were then interviewed separately by two
clinical psychologists trained in the administration of
the respective tests.
Models of longitudinal analysis
In order to study the factors associated with
changes in perceived QoL, we designed two mod-
els for grouping the scores obtained by patients on
the QoL-AD. The first was based on their score at
baseline (QoL-Baseline) and yielded three groups
that were comparable in terms of the number of sub-
jects in each: Low-QoL (< 33, n= 40), Medium-QoL
(33–37, n= 43), and High-QoL (> 37, n= 44). The
second model was based on the difference between
QoL-AD scores at baseline and 24-month follow-up
(QoL-Change), and here we established three groups
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based on the cut-off points that have generally been
used in previous studies [2, 4, 9, 14]: Decreased QoL
(≤ 3, n= 25), No change (± 2, n= 44), and Increased
QoL (≥ 3, n= 58). The number of groups was the
same at all the assessment points and in both models.
Statistical analysis
For the longitudinal analysis of data we applied
generalized estimating equations (GEE) and the Wald
χ2 statistic [32], in conjunction with a first-order
autoregressive working correlation matrix (AR1).
This approach enabled us to examine the general
effects of the independent variables on the depen-
dent variable (QoL-AD), with respect to the factors
time, patient group, and the interaction between the
two (Time∗Group), as well as the simple effects of
differences between the groups and the assessment
points.
The effect size of the difference between several
means was assessed using eta squared (η2), the value
of which was interpreted according to the follow-
ing criteria: <0.06, weak effect; 0.06–0.13, moderate
effect; >0.13, strong effect [33].
A multivariate analysis was first performed for
the whole sample, taking the QoL-AD score as the
dependent variable and patient factors (introduced
simultaneously) as independent variables, and spec-
ifying the parameter estimates at each of the three
measurement points (baseline, 12 months, and 24
months).
In order to detect the factors that predicted patients’
group assignment in the two models we performed
multinomial regression analyses at baseline, using the
‘Main effects’ option.
For hypothesis contrasts the level of statistical sig-
nificance was set at 0.05. All data processing and
analysis was performed using SPSS, v22.0 para Win-
dows (SPSS Inc.; Chicago).
RESULTS
Comparison of the study sample with
the baseline sample lost to follow-up
The study sample comprised the 127 patients
and caregivers who, from among the 221 initially
recruited, completed the full 24-month follow-
up. At baseline, the cases lost to follow-up
(n= 94) were older than those in the study sam-
ple (79.4 ± 6.9 versus 76.6 ± 7.3; z= 3.0, p= 0.002),
and they were also more impaired, presenting a
poorer cognitive status (MMSE = 17.2 ± 5.5 versus
19.1 ± 5.2; z= 2.4, p= 0.014), lower functional abil-
ity (DAD = 54.7 ± 9.5 versus 60.6 ± 10.0; z= 4.2,
p< 0.001), greater anosognosia (AQ-D = 38.9 ± 18.2
versus 30.2 ± 18.2; t= 3.4, p= 0.001), and more neu-
ropsychiatric symptoms (NPI = 31.2 ± 21.9 versus
20.9 ± 16.4; z= 3.9, p< 0.001).
Self-perceived QoL at baseline did not differ
significantly between lost cases and those who
were followed up (QoL-AD = 35.2 ± 4.9 versus
34.9 ± 4.7; z= 0.8, p= 0.402). Neither did the QoL-
AD scores of lost cases vary according to the severity
of dementia (GDS stage, χ2 = 4.0, p= 0.131).
Sociodemographic and clinical characteristics
of the study sample
At baseline, patients had a mean age of 76.6 ± 7.3
years, 82 of them (64.6%) were women, and 43
(33.9%) had received five or more years of formal
education.
Across the follow-up period we observed a
moderate deterioration in cognitive status (MMSE,
η2 = 0.10), a notable decrease in functional abil-
ity (DAD, η2 = 0.16), and an increased presence of
both neuropsychiatric symptoms (NPI, η2 = 0.03) and
anosognosia (AQ-D, η2 = 0.02), with a small effect
size. Patients’ ratings of their own QoL did not change
significantly during follow-up (p= 0.247). Complete
data shown in Table 1.
Factors affecting QoL ratings during follow-up
in the whole sample
The multivariate analysis (Table 2) showed that
depression had an important negative effect on self-
perceived QoL at all three assessment points. Greater
anosognosia had a positive effect on QoL-AD scores
that likewise continued across the follow-up period.
The positive effect of greater functional ability was
only significant at 12 and 24 months. Neuropsychi-
atric symptoms and cognitive status had no significant
effect on QoL scores.
The severity of dementia (assessed by GDS stage)
had little effect on QoL-AD scores, and the dif-
ferences between severity groups (GDS stages 4,
5, and 6) were not significant at baseline (Wald
χ2 = 1.0, p= 0.585), at 12 months (Wald χ2 = 0.8,
p= 0.661), or at 24 months (Wald χ2 = 0.3, p= 0.836).
With respect to the general effects of the model,
only Time was significant (Wald χ2 = 6.4, p= 0.040),
there being a slight increase in QoL-AD scores at
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Table 1
Sociodemographic and clinical data of patients
Baseline 12 months 24 months Differences
1 (n= 127) 2 (n= 127) 3 (n= 127) Test df p η2
Age, mean (SD) 76.6 (7.3) 77.8 (7.2) 79.0 (7.2)b 7.11 2 0.025
Women, n (%) 82 (64.6) 82 (64.6) 82 (64.6) 0.02 2 1.000
Marital status (widowed), n (%) 37 (30.1) 38 (30.9) 40 (32.0) 0.12 2 0.948
Schooling (> 5 years), n (%) 43 (33.9) 43 (33.9) 43 (33.9) 0.02 2 1.000
Cognition (MMSE), mean (SE) 19.1 (0.4) 16.8 (0.5)a 13.9 (0.6)b,c 106.13 2 <0.001 0.10
Function (DAD), mean (SE) 60.6 (0.8) 55.5 (0.8)a 50.0 (0.8)b,c 201.43 2 <0.001 0.16
Behavior (NPI), mean (SE) 20.9 (1.4) 23.4 (1.4) 28.6 (1.5)b,c 25.53 2 <0.001 0.03
Anosognosia (AQ-D), mean (SE) 30.2 (1.6) 34.5 (1.7) 37.9 (1.6)b 44.43 2 <0.001 0.02
Depression (GDS), mean (SE) 3.3 (0.2) 3.4 (0.2) 3.1 (0.2) 3.93 2 0.137 0.00
Quality of life (QoL-AD), mean (SE) 34.9 (0.4) 35.1 (0.4) 35.9 (0.4)b,c 16.93 2 <0.001 0.000
GDS stage, n (%)
GDS 4 68 (53.5) 33 (26.0) 12 (9.4) 83.62 4 <0.001
GDS 5 43 (33.9) 52 (40.9) 40 (31.5) V = 0.33
GDS 6 16 (12.6) 42 (33.1) 75 (59.1)
Family caregivers, n (%)
Spouse 72 (56.7) 72 (56.7) 70 (55.2) 0.22 4 0.992
Adult-child 51 (40.2) 52 (40.9) 53 (41.7) V = 0.01
Other 4 (3.1) 3 (2.4) 4 (3.1)
Living with caregiver, n (%)
Yes 101 (79.5) 100 (78.7) 97 (76.4) 0.42 2 0.819
No 26 (20.5) 27 (21.3) 30 (23.6) V= 0.03
1Kruskal-Wallis; 2Chi square test for categorical variables; V, Cramer’s V; 3Generalized estimating equations, Wald χ2, for time. Means,
estimated marginal; SE, standard error; Significant with Bonferroni post hoc contrasts: a1-2, b1-3, c2-3; η2 = Eta-squared (effect size);
p-values < 0.05 are shown in bold. MMSE, Mini-Mental State Examination; DAD, Disability Assessment in Dementia; NPI, Neuropsychiatric
Inventory; AQ-D, Anosognosia Questionnaire-Dementia; GDS, Geriatric Depression Scale; GDS stage, Global Deterioration Scale; QoL-AD,
Quality of Life in Alzheimer’s Disease scale.
Table 2
Multivariate analysis. QoL-AD, Time & Factors, in the overall sample
Parameter estimates
Model effects Baseline 12 months 24 months
χ2 df p B (SE) χ2 p B (SE) χ2 p B (SE) χ2 p
Time∗
Depression (GDS) 71.8 3 <0.001 –0.66 (0.10) 43.1 <0.001 –0.72 (0.11) 42.8 <0.001 –0.80 (0.11) 53.2 <0.001
Anosognosia (AQ-D) 43.0 3 <0.001 0.07 (0.01) 26.7 <0.001 0.07 (0.01) 26.3 <0.001 0.09 (0.01) 37.6 <0.001
Function (DAD) 8.0 3 0.044 0.02 (0.02) 1.3 0.247 0.06 (0.02) 5.8 0.015 0.06 (0.02) 4.7 0.029
Behavior (NPI) 5.6 3 0.130 –0.04 (0.02) 3.7 0.054 –0.02 (0.01) 3.3 0.068 –0.01 (0.00) 1.2 0.262
Cognition (MMSE) 5.8 3 0.120 0.09 (0.05) 2.7 0.095 –0.02 (0.04) 0.2 0.618 0.00 (0.03) 0.0 0.822
Method: Dependent variable = QoL-AD; Independent variables = introduced simultaneously. Generalized estimating equations, Wald χ2; B,
beta coefficient; SE, standard error; p-values < 0.05 are shown in bold. MMSE, Mini-Mental State Examination; DAD, Disability Assessment
in Dementia; NPI, Neuropsychiatric Inventory; AQ-D, Anosognosia Questionnaire-Dementia; GDS, Geriatric Depression Scale; QoL-AD,
Quality of Life in Alzheimer’s Disease scale.
24 months among patients in the GDS 6 group
(η2 = 0.007). Neither the between-groups difference
(Wald χ2 = 1.1, p= 0.553) or the Time∗Group inter-
action (Wald χ2 = 0.6, p= 0.960) were significant.
Regarding sociodemographic variables, men
scored slightly higher than women in the model
(Wald χ2 = 3.9, p= 0.046), although the differences
were only significant at 24 months. Participants
with >5 years of schooling also scored higher
(Wald χ2 = 6.4, p= 0.011), with differences being
significant at 12 and 24 months. In both cases the
effect sizes were small (d< 0.5). Age, relationship
to the caregiver (spouse/adult child), and living with
the caregiver were associated with no significant
differences between the groups, although scores
did increase slightly over the follow-up period for
younger participants (η2 = 0.00), those who lived
with the caregiver (η2 = 0.01), and those who were
cared for by a spouse (η2 = 0.00), the corresponding
effect sizes being very small.
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Table 3
Quality of life scores (QoL-AD) for the groups created in the two models
1. Baseline 2. 12 months 3. 24 months Simple effects
Mean (SE) Mean (SE) Mean (SE) χ2 df p
A. Groups QoL-Baseline
A1. Low-QoL 29.4 (0.4) 30.9 (0.7)a 31.7 (0.7)b 21.1 2 <0.001
A2. Medium 35.3 (0.2)d 35.5 (0.4)d 36.3 (0.4)d 5.5 2 0.064
A3 High-QoL 39.6 (0.3)e,f 38.6 (0.3)a,e,f 39.3 (0.4)e,f 9.5 2 0.008
Simple effects χ2 (df) p 341.8 (2)<0.001 95.2 (2)<0.001 79.0 (2)<0.001
• Model χ2 (df) p Time: 18.1 (2) <0.001; Groups: 172.3 (2) <0.001; Time∗groups: 18.0 (4) 0.001
B. Groups QoL-Change
B1. Decreased-QoL 37.5 (1.0) 34.1 (1.1)a 33.5 (1.2)b 65.8 2 <0.001
B2. No change 34.8 (0.6) 34.7 (0.7) 35.0 (0.6) 4.8 2 0.090
B3. Increased-QoL 34.0 (0.5)e 35.9 (0.4)a 37.6 (0.5)b,c,e,f 283.7 2 <0.001
Simple effects χ2 (df) p 8.1 (2) 0.017 3.4 (2) 0.182 15.9 (2) <0.001
• Model χ2 (df) p Time: 5.9 (2) 0.051; Groups: 1.7 (2) 0.427; Time∗ groups: 300.4 (4) <0.001
Generalized estimating equations, Wald χ2; Means, estimated marginal; SE, standard error; Significant with Bonferroni post hoc contrasts:
a1-2, b1-3, c2-3, dA1/B1- A2/B2, eA1/B1-A3/B3, f A2/B2-A3/B3. p-values < 0.05 are shown in bold. QoL-AD, Quality of Life in Alzheimer’s
Disease scale; AQ-D, Anosognosia Questionnaire-Dementia; GDS, Geriatric Depression Scale; NPI, Neuropsychiatric Inventory; DAD,
Disability Assessment in Dementia; MMSE, Mini-Mental State Examination.
Variability in baseline QoL-AD scores
and clinical factors
In the QoL-Baseline model the baseline scores
on the QoL-AD were as follows: Low = 29.4 ± 2.7;
Medium = 35.3 ± 1.4; High = 39.6 ± 2.3 (χ2 = 112.6,
p< 0.001; η2 = 0.78). In the QoL-Change model
the baseline scores were: Decreased = 37.5 ± 5.5;
No change = 34.8 ± 4.6; Increased = 34.0 ± 4.0 (χ2 =
9.4, p= 0.009; η2 = 0.07). Although the differences
between groups were significant in both models, the
between-group variability was greater in the QoL-
Baseline model, with a large effect size. Conversely,
the within-group variability was lower in the QoL-
Baseline model, with smaller standard deviations.
At baseline the clinical factors that were signifi-
cantly associated with between-group variability in
the QoL-Baseline model were depression (GDS):
Low = 5.2 ± 3.0, Medium = 3.3 ± 2.4, High = 1.6 ±
1.6 (χ2 = 34.1, p< 0.001; η2 = 0.26); functional abil-
ity (DAD): Low = 57.5 ± 9.3, Medium = 62.5 ± 10.3,
High = 61.5 ± 9.8 (χ2 = 6.5, p= 0.038; η2 = 0.04);
and neuropsychiatric symptoms (NPI): Low = 24.3
± 17.4, Medium = 21.3 ± 15.7, High = 17.5 ± 15.8
(χ2 = 6.3, p= 0.043; η2 = 0.02). In the QoL-Change
model none of the clinical factors was associated with
significant variability between the groups.
In order to examine the predictive ability of the
baseline QoL-AD score on QoL scores at 24 months
we conducted a linear regression analysis. The results
showed that the baseline QoL score was a good pre-
dictor of QoL-AD scores at 24 months (R2 = 0.588,
= 0.76, t= 13.3, p< 0.001.
Changes over time in QoL-AD scores in the two
models of analysis
For the groups created in the QoL-Baseline model
the GEE indicated that the general effects were sig-
nificant for Time, Group, and for the Time∗Group
interaction. Regarding the simple effects, there
were important between-group differences at all
three assessment points (η2; T1 = 0.78, T2 = 0.45;
T3 = 0.41), with higher scores being observed in
the High-QoL group. During follow-up, scores in
the Low-QoL group increased, whereas those in the
High-QoL group decreased, the effect size being
weak in both cases (η2; Low = 0.04, High = 0.02).
For the groups created in the QoL-Change model
the GEE indicated that the general effects were only
significant for the Time∗Group interaction. Regard-
ing the simple effects, a between-groups difference
of moderate magnitude was observed at baseline
(η2 = 0.07) and at 24 months (η2 = 0.11). During
follow-up, significant differences, with a moderate
effect size, were only present in the Decreased-
QoL group (η2 = 0.08) and the Increased-QoL group
(η2 = 0.12). Complete data are shown in Table 3.
Figures 1A and 1B show the change in QoL scores
for the three groups in the QoL-Baseline and QoL-
Change models, respectively.
The proportion of patients classified as GDS 4,
5 and 6 did not change significantly in either the
QoL-Baseline model (Baseline, χ2 = 0.4, p= 0.978;
12 months, χ2 = 1.4, p= 0.835; 24 months, χ2 = 7.4,
p= 0.115) or the QoL-Change model (Baseline,
χ2 = 6.6, p= 0.153; 12 months, χ2 = 3.3, p= 0.501; 24
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Fig. 1. Two models for analyzing QoL across follow up. Wald χ2 = Generalized estimating equations. η2 = Eta-squared (effect size).
months, χ2 = 3.0, p= 0.557). Similarly, there were no
significant changes in either model (QoL-Baseline or
QoL-Change) in the proportions of subjects accord-
ing to age group (± 77), gender, years of schooling
(± 5 years), type of family caregiver (spouse/adult
child), or living with the caregiver.
Clinical variables in the QoL-Baseline model
during follow-up
The data for the main variables in relation to
the three subgroups formed using the QoL-Baseline
model are shown in Table 4.
The effect of depression (GDS) was strongest in
the Low-QoL group. There were important between-
group differences at each assessment point (η2;
T1 = 0.26, T2 = 0.24, T3 = 0.26), but in none of the
groups was a significant change observed in this
variable across follow-up. When depression was ana-
lyzed with the NPI (Depression subscale) the results
obtained were consistent with those from the GDS:
The Low-QoL group scored higher and the High-QoL
group lower, although the effect sizes were smaller
than those for the GDS (η2; T1 = 0.13, T2 = 0.09,
T3 = 0.10).
With respect to anosognosia the lowest scores cor-
responded to the Low-QoL group and the highest
scores to the High-QoL group, the opposite of the
effect observed for depression. Between-group dif-
ferences increased across the three assessment points
(η2; T1 = 0.04, T2 = 0.06, T3 = 0.07). During follow-
up, anosognosia increased in all three groups, most
notably in the High-QoL group, although the effect
sizes were weak (η2; Low = 0.01, Medium = 0.02,
High = 0.04).
The greatest number of neuropsychiatric symp-
toms was presented by patients in the Low-QoL
group. Between-group differences were only sig-
nificant at 24 months, with a weak effect size (η2
= 0.049). During follow-up, all the groups showed an
increase in NPI scores, although the effect sizes were
weak (η2; Low = 0.05, Medium = 0.02, High = 0.04).
With respect to functional impairment the
between-group differences were small, and only
at baseline did the Low-QoL group score signifi-
cantly lower (η2 = 0.04). By contrast, all three groups
showed a notable deterioration across the follow-up
period (η2; Low = 0.12, Medium = 0.16, High = 0.21),
with the change being greatest in the High-QoL
group.
The results for cognitive status were similar to
those for functional ability: The between-group dif-
ferences were not significant at any of the assessment
points, but there was a moderate-to-large deteri-
oration in cognitive function in all three groups
across follow-up (η2; Low = 0.09, Medium = 0.08,
High = 0.15), with the greatest change corresponding
to the High-QoL group.
Clinical variables in the QoL-Change model
during follow-up
The data for the main variables in relation to
the three subgroups formed using the QoL-Change
model are shown in Supplementary Table 1.
Depression scores (GDS) were always lower in the
Increased-QoL group, although the between-group
differences were only significant, with a moderate
effect size, at 24 months (η2 = 0.07). Only in the
Increased-QoL group was a decrease in scores, with a
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Table 4
Groups according to the QoL-Baseline model. Scores for clinical variables
1. Baseline 2. 12 months 3. 24 months Simple effects
Mean (SE) Mean (SE) Mean (SE) χ2 df p
Depression (GDS)
Low-QoL 5.2 (0.4) 5.2 (0.5) 4.9 (0.4) 3.5 2 0.171
Medium 3.3 (0.3)d 3.5 (0.3)d 3.3 (0.3)d 0.4 2 0.810
High-QoL 1.6 (0.2)e,f 1.7 (0.2)e,f 1.3 (0.2)e,f 5.3 2 0.069
Simple effects χ2 (df) p 49.2 (2)<0.001 46.6 (2)<0.001 47.0 (2)<0.001
• Model χ2 (df) p Time: 4.0 (2) 0.132; Groups: 58.6 (2)<0.001; Time∗groups: 0.9 (4) 0.913
Depression (NPI)
Low-QoL 3.2 (0.5) 3.7 (0.5) 3.9 (0.6) 1.1 2 0.569
Medium 3.1 (0.4) 2.6 (0.5) 1.6 (0.3)c,d 11.3 2 0.003
High-QoL 1.0 (0.2)e,f 1.2 (0.3)e 1.4 (0.5)e 1.0 2 0.587
Simple effects χ2 (df) p 26.0 (2) <0.001 13.9 (2) 0.001 12.0 (2) 0.002
• Model χ2 (df) p Time: 0.2 (2) 0.863; Groups: 22.6 (2) <0.001; Time∗groups: 12.0 (4) 0.017
Anosognosia (AQ-D)
Low-QoL 26.5 (2.8) 30.5 (3.1)a 32.6 (2.9)b 14.4 2 0.001
Medium 28.4 (2.7) 31.5 (3.0) 36.2 (2.7)b,c 13.4 2 0.001
High-QoL 35.5 (2.5) 40.9 (2.3)a,e,f 44.4 (2.3)b,c,e 19.2 2 <0.001
Simple effects χ2 (df) p 6.3 (2) 0.042 9.4 (2) 0.009 10.9 (2) 0.004
• Model χ2 (df) p Time: 45.1 (2) <0.001; Groups: 10.1 (2) 0.006; Time∗groups: 3.0 (4) 0.555
Behavior (NPI)
Low-QoL 24.3 (2.7) 28.0 (2.7) 34.4 (2.8)b 8.8 2 0.012
Medium 21.3 (2.3) 20.4 (2.2) 26.1 (2.9)c 7.3 2 0.025
High-QoL 17.5 (2.3) 22.2 (2.3) 25.8 (2.2)b 15.8 2 <0.001
Simple effects χ2 (df) p 3.6 (2) 0.158 4.7 (2) 0.092 6.4 (2) 0.039
• Model χ2 (df) p Time: 25.2 (2)<0.001; Groups: 6.7 (2) 0.035; Time∗groups: 3.9 (4) 0.415
Function (DAD)
Low-QoL 57.5 (1.4) 52.6 (1.5)a 48.8 (1.4)b,c 66.6 2 <0.001
Medium 62.5 (1.5) 56.9 (1.6)a 51.2 (1.4)b,c 67.2 2 <0.001
High-QoL 61.5 (1.4) 56.7 (1.2)a 49.9 (1.3)b,c 82.4 2 <0.001
Simple effects χ2 (df) p 6.3 (2) 0.042 4.9 (2) 0.082 1.3 (2) 0.506
• Model χ2 (df) p Time: 209.6 (2) <0.001; Groups: 4.3 (2) 0.112; Time∗groups: 8.9 (4) 0.063
Cognition (MMSE)
Low-QoL 17.7 (0.8) 15.4 (1.0)a 12.5 (1.1)b,c 39.9 2 <0.001
Medium 19.4 (0.7) 16.9 (0.8)a 15.0 (0.9)b,c 38.3 2 <0.001
High-QoL 20.1 (0.7) 18.0 (0.7)a 14.3 (1.0)b,c 34.0 2 <0.001
Simple effects χ2 (df) p 4.5 (2) 0.101 4.1 (2) 0.123 2.7 (2) 0.255
• Model χ2 (df) p Time: 108.5 (2) <0.001; Groups: 3.8 (2) 0.148; Time∗groups: 6.1 (4) 0.189
Generalized estimating equations, Wald χ2; Means, estimated marginal; SE, standard error; Significant with Bonferroni post hoc contrasts:
a1-2, b1-3, c2-3, dLow-Medium, eLow-High, f Medium-High. p-values < 0.05 are shown in bold. QoL-AD, Quality of Life in Alzheimer’s
Disease scale; AQ-D, Anosognosia Questionnaire-Dementia; GDS, Geriatric Depression Scale; NPI, Neuropsychiatric Inventory; DAD,
Disability Assessment in Dementia; MMSE, Mini-Mental State Examination.
weak effect size (η2 = 0.01), observed during follow-
up. When depression was analyzed with the NPI
(Depression subscale) the results were consistent
with those obtained from the GDS: The Increased-
QoL group had the lowest scores. However, the
differences between groups were not significant at
any of the assessment points, and the effect sizes were
small (η2; T1 = 0.01, T2 = 0.03, T3 = 0.01).
With respect to anosognosia the highest scores cor-
responded to the Increased-QoL group and the lowest
scores to the Decreased-QoL group, although the
between-group differences only showed a moderate
effect at 24 months (η2 = 0.06). During follow-up,
anosognosia increased in all the groups, although
the effect sizes were weak (η2; Decreased = 0.00, No
change = 0.02, Increased = 0.04).
The greatest number of neuropsychiatric symp-
toms was presented by patients in the Increased-QoL
group, although between-group differences were not
significant. Across follow-up a significant change,
with a weak effect size, was only observed in the No
change (η2 = 0.04) and the Increased-QoL (η2 = 0.03)
groups.
With respect to functional impairment the
between-group differences were not significant at
any of the assessment points, but each of the
three groups showed a notable deterioration across
follow-up (η2; Decreased = 0.19, No Change = 0.15,
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Table 5
Clinical variables. Multinomial logistic regression analysis at baseline assessment
Method: Enter together B (SE) Wald p OR 95% CI
A. Groups QoL-Baseline
Low QoL (<33 QoL)
Depression (GDS) 0.18 (0.09) 3.89 0.048 1.20 1.00–1.45
Anosognosia (AQ-D) –0.04 (0.02) 3.71 0.054 0.95 0.91–1.00
Function (DAD) –0.08 (0.03) 4.57 0.032 0.92 0.85–0.99
Behavior (NPI) 0.01 (0.01) 0.92 0.335 1.01 0.98–1.05
Cognition (MMSE) –0.04 (0.05) 0.63 0.426 0.95 0.86–1.06
High QoL (>37 QoL)
Depression (GDS) –0.38 (0.13) 8.29 0.004 0.68 0.52–0.88
Anosognosia (AQ-D) 0.06 (0.02) 6.28 0.012 1.07 1.01–1.13
Function (DAD) 0.02 (0.04) 0.40 0.524 1.02 0.94–1.11
Behavior (NPI) –0.04 (0.02) 5.74 0.017 0.95 0.91–0.99
Cognition (MMSE) 0.08 (0.05) 2.65 0.103 1.08 0.98–1.20
Reference group: Medium QoL (33–37 QoL)
B. Groups QoL-Change
Decreased (≤ 3 QoL)
Depression (GDS) –0.09 (0.10) 0.89 0.344 0.90 0.74–1.10
Anosognosia (AQ-D) –0.01 (0.02) 0.27 0.597 0.98 0.94–1.03
Function (DAD) 0.04 (0.04) 0.96 0.327 1.04 0.96–1.13
Behavior (NPI) 0.03 (0.02) 1.98 0.159 1.03 0.98–1.07
Cognition (MMSE) 0.03 (0.05) 0.37 0.540 1.03 0.92–1.15
Increased (≥ 3 QoL)
Depression (GDS) –0.18 (0.08) 4.69 0.030 0.83 0.70–0.98
Anosognosia (AQ-D) –0.00 (0.01) 0.24 0.624 0.99 0.95–1.02
Function (DAD) 0.00 (0.03) 0.02 0.866 1.00 0.94–1.06
Behavior (NPI) 0.02 (0.01) 1.40 0.236 1.02 0.98–1.05
Cognition (MMSE) –0.02 (0.04) 0.28 0.595 0.97 0.89–1.06
Reference group: No change QoL (±2 QoL)
B, unstandardized coefficient; SE, standard error; OR, odds ratio; CI, confidence interval QoL-AD, Quality of Life in Alzheimer’s Disease
scale; AQ-D, Anosognosia Questionnaire-Dementia; GDS, Geriatric Depression Scale; NPI, Neuropsychiatric Inventory; DAD, Disability
Assessment in Dementia; MMSE, Mini-Mental State Examination.
Increased = 0.17). The results for cognitive status
were similar to those for functional ability: No sig-
nificant between-group differences were observed,
but there was a moderate-to-large deterioration
in cognitive function in all three groups across
follow-up (η2; Decreased = 0.22, No change = 0.06,
Increased = 0.12).
Multinomial regression analysis of the groups
of patients at baseline assessment
In the multinomial regression we took the inter-
mediate group in each model (i.e. Medium in the
QoL-Baseline model and No change in the QoL-
Change model) as the reference group (Table 5).
In the QoL-Baseline model the predictors for the
Low-QoL group were greater depression and poorer
functional ability. In the High-QoL group the pre-
dictors were less depression, more anosognosia, and
fewer neuropsychiatric symptoms.
In the QoL-Change model there were no significant
predictors for the Decreased-QoL group, and only
less depression was a predictor in the Increased-QoL
group.
DISCUSSION
Factors associated with QoL in the sample
as a whole
Depression, neuropsychiatric symptoms, anosog-
nosia, and functional ability were all shown to be
relevant when analyzing the overall sample, although
the most important factors were anosognosia and
depression.
The association between greater depression and
lower scores on self-perceived QoL has been widely
reported in longitudinal and cross-sectional studies
of community samples [5, 6, 8, 11, 18, 34–38] and
of patients attending day centers [39] or living in
residential care [2, 4, 40]. Furthermore, the results
obtained have been similar despite the variety of
instruments used to assess depression: Cornell Scale
for Depression in Dementia (CSDD) [2, 4], Center for
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Epidemiologic Studies-Depression Scale (CES-D)
[6], Hospital Anxiety and Depression Scale (HADS)
[8], NPI-Depression [5, 11, 37], Geriatric Depression
Scale (GDS) [18, 36, 38, 39], Hamilton Depression
Scale (HRSD) [35], and the Beck Depression Inven-
tory (BDI) [34].
Although depression is the neuropsychiatric symp-
tom most widely reported to be associated with poorer
QoL, this association with impaired QoL has also
been found for the total NPI score [5, 11, 17], as
well as for other specific neuropsychiatric symptoms,
including apathy [39], anxiety [2, 4], agitation [40],
and psychotic symptoms assessed by the NPI (Delu-
sions, Hallucinations) [5].
The association between greater anosognosia and
a more positive view of QoL among patients with
dementia has been well documented in both cross-
sectional [41–45] and longitudinal studies [10, 11,
18].
Finally, some studies have also reported an asso-
ciation between better functional ability and higher
self-ratings of QoL [3, 6].
Anosognosia, depression, and quality of life
The relationship between anosognosia and depres-
sion, however, requires a more detailed analysis. The
first authors to report an inverse relationship between
anosognosia and depression were Sevush and Leve
[46]. Subsequent research confirmed this inverse
association, suggesting that depression is more likely
to be present when patients have a greater awareness
of their deficits (less anosognosia), and therefore that
it is a reaction to the process of deterioration [25,
47–49].
The combination of these two factors and their rela-
tionship to perceived QoL has also been investigated,
with similar findings being obtained: Greater anosog-
nosia was associated with less depression and a more
positive view of QoL, and vice-versa, that is, poorer
self-perceived QoL was linked to more depression
and less anosognosia [11, 18, 50, 51].
Comparison of the QoL-Baseline
and QoL-Change models
Focusing on the baseline scores in the two models
the QoL-Baseline model showed greater between-
group variability (better differentiation between
groups) and less within-group variability (greater
homogeneity of subjects in each group) than did the
QoL-Change model. It should also be noted that cer-
tain clinical factors (depression, functional ability,
and neuropsychiatric symptoms) were shown to be
significantly associated with this between-group vari-
ability in the QoL-Baseline model. These results
support our initial hypothesis and the findings of
previous studies in community samples [6, 7, 9]
regarding the superiority of the QoL-Baseline model
for the analysis of data, as well as the good predictive
ability of the baseline QoL score.
In addition, the analysis of the QoL-Baseline
model showed that the influence of the clinical vari-
ables differed according to the groups. Depression
was greater in the Low-QoL group and lower in the
High-QoL group. The opposite pattern was observed
for anosognosia, that is, scores were lower in the Low-
QoL group and higher in the High-QoL group. These
distributions were the same at all three assessment
points. The Low-QoL group also presented more neu-
ropsychiatric symptoms and poorer functional ability.
The analysis of the QoL-Change model showed less
variability between the groups formed according to
this model. The only notable finding was that the
Increased-QoL group presented less depression and
greater anosognosia, although this was only the case
at 24 months.
It should be noted that when scores on the NPI
Depression subscale were used as a measure of
depression in the groups of both models, the results
were consistent with those obtained with the GDS,
although their statistical relevance was reduced.
This finding is in line with previous research [39].
Depression is clearly the most important clinical
factor associated with poorer self-perceived QoL in
both models (Low-QoL group and Decreased-QoL
group), although the statistical effect is more notable
in the QoL-Baseline model.
The results of this study confirm that the self-
rating of QoL at baseline (Low, High) is more
relevant than the change in QoL ratings over time
(Decreased, Increased). Although a number of previ-
ous studies [2, 4, 9, 14] have used a model based on
deterioration-stability-improvement in QoL scores
across follow-up, the model based on the baseline
QoL score seems to offer certain advantages. From a
psychometric point of view the QoL-Baseline model
was a better predictor of perceived QoL at 24 months,
and it also enabled us to observe the effect of the
different variables in each group. This model would
likewise be useful from a clinical point of view. Given
that QoL scores have been shown to remain relatively
stable over time in both community samples [3, 5–11]
and residential populations [2, 4, 14], the baseline
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score could be used to predict how a patient is likely
to evolve, thus enabling suitable interventions to be
targeted at the factors known to influence QoL, espe-
cially depression and anosognosia/cognitive status.
Clinical implications
The results of this study suggest that a longitudinal
analysis of self-perceived QoL among patients with
AD should use a model in which groups are created
according to baseline scores, since this model is better
than one based on a change in scores when it comes to
identifying trajectories and predictors of QoL. This
recommendation follows from the fact that the key
feature of QoL scores is not change over time but,
rather, the stability of the different score ranges.
In terms of intervention, the assessment of a
patient’s baseline status, covering depression, cog-
nitive and functional ability, and neuropsychiatric
symptoms, should serve as a platform on which to
implement strategies that can help ameliorate the
negative effects of the condition, especially among
patients with poor perceived QoL. There is an exten-
sive literature on non-pharmacological interventions
in patients with dementia, although they appear to
have only a moderate effect on the different variables
involved. A recent review of six randomized con-
trolled studies found beneficial effects with respect
to depression and anxiety symptoms [52]. Music
therapy has also been shown to have some benefits
with regard to reducing neuropsychiatric symptoms
[53, 54], improving symptoms of anxiety and depres-
sion [55, 56], enhancing cognitive performance and
quality of life [55, 57], and even for improving or
stabilizing certain aspects of self-awareness [58].
Other studies have found that cognitive stimulation
therapy can improve cognition [59, 60] and qual-
ity of life [59, 61], reducing apathy and symptoms
of depression. Reminiscence programs appear to
improve symptoms of depression and interpersonal
relationships [62, 63]. Physical exercise reduced
neuropsychiatric symptoms in patients with mild
dementia [64]. A program of therapeutic education
for patients and caregivers improve the quality of life
[65]. Finally, multicomponent programs have been
shown to improve apathy, anxiety, depression, and
quality of life [66].
Limitations and future research
The main limitation of this study is that depres-
sion and anosognosia were not assessed clinically,
the data being based solely on self- and informant
report measures.
Our results are unlikely to have been seriously
affected by the loss of some cases to follow-up, since
QoL scores do not appear to be influenced by the
severity of dementia.
Future research should nonetheless aim to replicate
the present analysis with patients in residential care
facilities, since, although the severity of dementia was
not shown here to have an effect on perceived QoL, it
is possible that community and institutionalized sam-
ples would yield different results. Indeed, whereas all
research in community samples reports stability of
QoL scores over follow-up [3, 5–13, 18], these scores
have been reported to decrease over time in some res-
idential samples [15–17], probably due to increased
severity of dementia in these patients. It would also
be interesting to examine possible changes in QoL
related to pharmacological and non-pharmacological
interventions, and also to analyze in greater depth
the variability associated with family and contextual
factors.
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